Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Disparate post-relapse survival outcomes by race/ethnicity for children with B-cell acute lymphoblastic leukemia: An analysis from the recall-1 study

View Full Paper
Ask AI
Bookmark
Share

Authors

CECaitlin W. ElgartenVFVanessa A. FabrizioAHAnurekha G. Hall

Discussion

Loading...

Member takes

Overview

Analysis demonstrates disparate survival outcomes in pediatric B-ALL across race/ethnicity, suggesting treatment access may differ.

Key Points

  • Pediatric patients with high-risk 1st relapse of B-ALL show significant survival disparities by race.
  • Hematopoietic cell transplant outcomes indicate a two-fold increased hazard of death for NHB patients compared to NHW.
  • Utilization of cell therapy for B-ALL appears similar across different race/ethnic groups in this cohort.
  • Disparities in overall survival highlight the necessity of considering race/ethnicity in treatment and care for pediatric patients.

Cite This Study

Elgarten et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d51dhttps://doi.org/10.1182/blood-2025-4525
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world post-relapse survival outcomes in children with Acute Myeloid Leukemia by race and ethnicity2025
  2. 2Role of race and ethnicity in survival among children/young adults with relapsed ALL: a Children's Oncology Group report2025
  3. 3Outcomes after relapse for adolescent and young adult patients with ALL: Results from the Children's oncology group2025
  4. 4Optimal therapy for pediatric B-ALL in first relapse: Comparative effectiveness of blinatumomab to hematopoietic cell transplantation versus CD19 CAR T cell therapy2025
  5. 5Predictors of survival with and without allogeneic stem cell transplantation after first salvage therapy with blinatumomab and/or inotuzumab ozogamicin for Relapsed/Refractory B-cell acute lymphoblastic leukemia2025 · 1 citations